CL2014000328A1 - Metodo para preparar composicion que contiene un portador de oxigeno termoestable; composicion farmacéutica que comprende hemoglobina. - Google Patents

Metodo para preparar composicion que contiene un portador de oxigeno termoestable; composicion farmacéutica que comprende hemoglobina.

Info

Publication number
CL2014000328A1
CL2014000328A1 CL2014000328A CL2014000328A CL2014000328A1 CL 2014000328 A1 CL2014000328 A1 CL 2014000328A1 CL 2014000328 A CL2014000328 A CL 2014000328A CL 2014000328 A CL2014000328 A CL 2014000328A CL 2014000328 A1 CL2014000328 A1 CL 2014000328A1
Authority
CL
Chile
Prior art keywords
hemoglobin
oxygen carrier
pharmaceutical composition
composition containing
preparing
Prior art date
Application number
CL2014000328A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Kwok Chu Butt
Original Assignee
Billion King Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Billion King Int Ltd filed Critical Billion King Int Ltd
Publication of CL2014000328A1 publication Critical patent/CL2014000328A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000328A 2011-08-31 2014-02-10 Metodo para preparar composicion que contiene un portador de oxigeno termoestable; composicion farmacéutica que comprende hemoglobina. CL2014000328A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529279P 2011-08-31 2011-08-31
US13/225,797 US20130052232A1 (en) 2011-08-31 2011-09-06 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US13/275,366 US8106011B1 (en) 2011-08-31 2011-10-18 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking

Publications (1)

Publication Number Publication Date
CL2014000328A1 true CL2014000328A1 (es) 2014-07-11

Family

ID=45508128

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000328A CL2014000328A1 (es) 2011-08-31 2014-02-10 Metodo para preparar composicion que contiene un portador de oxigeno termoestable; composicion farmacéutica que comprende hemoglobina.

Country Status (22)

Country Link
US (2) US20130052232A1 (es)
EP (1) EP2750700B1 (es)
JP (1) JP6148673B2 (es)
KR (1) KR101794932B1 (es)
CN (1) CN103796671A (es)
AP (1) AP3848A (es)
AU (1) AU2012300475B2 (es)
BR (1) BR112014003480A2 (es)
CA (1) CA2844510C (es)
CL (1) CL2014000328A1 (es)
DK (1) DK2750700T3 (es)
EA (1) EA027238B1 (es)
ES (1) ES2664589T3 (es)
IL (1) IL231198A0 (es)
MA (1) MA35358B1 (es)
MX (1) MX352941B (es)
MY (1) MY163300A (es)
PH (1) PH12014500471B1 (es)
SG (1) SG2014011498A (es)
TW (2) TWI408145B (es)
WO (1) WO2013032828A2 (es)
ZA (1) ZA201401518B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849448C (en) 2011-09-06 2020-03-24 Billion King International Limited Oral delivery for hemoglobin based oxygen carriers
CN109731098A (zh) * 2012-03-29 2019-05-10 桑加特公司 双阿司匹林交联聚乙二醇化血红蛋白
EP3922643A1 (en) 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
CA2911414C (en) * 2013-05-13 2018-09-11 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
WO2016149562A2 (en) 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
CA3149234A1 (en) * 2019-08-29 2021-03-04 Kwok Chu Butt Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof
CN110522904A (zh) * 2019-09-09 2019-12-03 润方（北京）生物医药研究院有限公司 一种抑制血压升高的聚合血红蛋白
EP4041193A1 (en) * 2019-10-11 2022-08-17 Medical Technology Associates II, Inc. Stabilized hemoglobin compositions and pharmaceutical formulations thereof
US11857605B2 (en) * 2021-03-01 2024-01-02 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
FR2548671B1 (fr) 1983-07-07 1986-05-02 Merieux Inst Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US5464814A (en) 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
JPH0750329B2 (ja) 1986-06-23 1995-05-31 富士写真フイルム株式会社 画像形成材料
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
EP0379534A4 (en) 1988-06-15 1991-03-13 Baxter International Inc. Method of purifying cross-linked hemoglobin
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5741894A (en) 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
JP2000502058A (ja) 1995-11-30 2000-02-22 ソマトジェン，インコーポレイテッド ヘモグロビン架橋の際の機能性制御のための方法
CN1161406C (zh) 1996-03-21 2004-08-11 森格沃尔德·维帕克尤恩根有限责任公司 多层薄膜、其制备方法及其应用
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
US6054427A (en) 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US6518010B2 (en) 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
CA2444590C (en) 2001-04-18 2009-12-01 Robert L. Mcginnis Stabilized hemoglobin solutions
JP4260417B2 (ja) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト 溶液を輸送し脱酸素するためのシステム及び方法
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
AU2003299700B2 (en) 2002-12-23 2009-03-26 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same
WO2004066953A2 (en) 2003-01-29 2004-08-12 Northfield Laboratories, Inc. Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing
JP5346468B2 (ja) 2004-10-29 2013-11-20 シーラス コーポレイション 赤血球不活性化プロセスのための改善されたクエンチング方法
WO2007065265A1 (en) 2005-12-08 2007-06-14 Ronald Kluger Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7795401B2 (en) 2006-09-06 2010-09-14 National Chung Cheng University Modified hemoglobin with allosteric effector conjugated
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
TWI526218B (zh) 2016-03-21
JP6148673B2 (ja) 2017-06-14
KR20140060510A (ko) 2014-05-20
CA2844510C (en) 2018-09-11
TW201313736A (zh) 2013-04-01
WO2013032828A8 (en) 2013-07-04
US20130052232A1 (en) 2013-02-28
MY163300A (en) 2017-09-15
CA2844510A1 (en) 2013-03-07
TW201341396A (zh) 2013-10-16
NZ620913A (en) 2016-03-31
EP2750700A2 (en) 2014-07-09
MX352941B (es) 2017-12-14
EA027238B1 (ru) 2017-07-31
AU2012300475B2 (en) 2017-04-06
AU2012300475A1 (en) 2014-02-27
MA35358B1 (fr) 2014-08-01
AP2014007545A0 (en) 2014-03-31
CN103796671A (zh) 2014-05-14
KR101794932B1 (ko) 2017-11-07
SG2014011498A (en) 2014-04-28
EP2750700B1 (en) 2017-12-27
MX2014002327A (es) 2014-09-15
ZA201401518B (en) 2014-12-23
WO2013032828A2 (en) 2013-03-07
PH12014500471B1 (en) 2019-01-25
WO2013032828A3 (en) 2013-05-10
DK2750700T3 (en) 2018-04-16
EA201400169A1 (ru) 2014-06-30
AP3848A (en) 2016-09-30
BR112014003480A2 (pt) 2017-03-14
US8106011B1 (en) 2012-01-31
TWI408145B (zh) 2013-09-11
JP2014525441A (ja) 2014-09-29
IL231198A0 (en) 2014-04-30
PH12014500471A1 (en) 2014-05-05
ES2664589T3 (es) 2018-04-20
EP2750700A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
PL2779877T3 (pl) Nośnik i kapsułka do przyrządzania napoju poprzez odwirowywanie, układ i sposób do przyrządzania napoju poprzez odwirowywanie
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
BR112014028024A2 (pt) método para processar um material de biomassa.
HRP20190032T1 (hr) Pegilirani liposomi, namijenjeni unosu rna koja kodira imunogen
IT1399831B1 (it) Macchina per realizzare imballi.
HRP20260388T1 (hr) Postupak pripreme biogenog reagensa s visokim udjelom ugljika
BR112014003798A2 (pt) método para fabricar um composto, e, composto
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
EP2852687A4 (en) PROCESS FOR SAMPLE PREPARATION
BR112014015294A2 (pt) método cosmétido; de referência de cor, especialmente para implementar método; sistema para implementar o metodo, pacote de software de computador para implementar o método
LT3406251T (lt) Piruvatkinazės aktyvatoriai, skirti panaudoti terapijai
BR112013013076A2 (pt) Método para operar elevadores
BRPI1010950A2 (pt) método para preparação de emulsão carregada de fármaco.
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
ZA201502259B (en) Clean method for preparing d,l-methionine
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
DK2773633T3 (da) Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf.
BR112015002724A2 (pt) métodos para produzir um composto não catabólico heterólogo e para produzir um isoprenóide heterólogo , e , composição de fermentação.
CL2013003111A1 (es) Metodo para la preparacion de una composicion farmaceutica que contiene un transportador de oxigeno purificado y termicamente estable, que contiene el transportador de oxigeno hemoglobina, donde la hemoglobina incluye a hemoglobina polimerica entrecruzada.
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
BR112014009360A2 (pt) folha, e, método para formar folha sequestrante de oxigênio
IT1399912B1 (it) Processo di preparazione di ritodrina cloridrato.
EP2692721A4 (en) DIAMOND COMPOUND WITH A SULFURIC ACID GROUP AND METHOD OF MANUFACTURING THEREOF